Señales en vivo de ONCR | Maximiza tus Ganancias con Getagraph.com

Live Chart Being Loaded With Signals

Commentary (29 dic 2023 @ 14:55):

Stats
Volumen de hoy	135 947
Volumen promedio	108 675
Capitalización de mercado	3.29M
EPS	$0 ( 2024-03-21 )
Próxima fecha de ganancias	( $0 ) 2024-05-20
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.0362
ATR14	$0.00400 (3.17%)

Insider Trading

Date	Person	Action	Amount	type
2023-06-06	Shea Brian J.	Sell	0	Common Stock
2023-06-06	Shea Brian J.	Sell	15 000	Employee Stock Option (right to buy)
2023-06-06	Shea Brian J.	Sell	3 744	Employee Stock Option (right to buy)
2023-06-06	Shea Brian J.	Sell	14 700	Employee Stock Option (right to buy)
2023-06-06	Shea Brian J.	Sell	19 100	Employee Stock Option (right to buy)

INSIDER POWER
-41.90
Last 97 transactions
Buy: 2 441 000 \| Sell: 694 654

Volumen Correlación

Largo: 0.41 (neutral)

Corto: 0.27 (neutral)

Signal:(89.911) Neutral

Oncorus, Inc. Correlación

10 Correlaciones Más Positivas

10 Correlaciones Más Negativas

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Oncorus, Inc. Correlación - Moneda/Commodity

-0.26
( neutral )

-0.20
( neutral )

0.00
( neutral )

-0.39
( neutral )

-0.15
( neutral )

Oncorus, Inc. Finanzas

Annual	2022
Ingresos:	$0
Beneficio Bruto:	$0 (0.00 %)
EPS:	$-3.02

FY	2022
Ingresos:	$0
Beneficio Bruto:	$0 (0.00 %)
EPS:	$-3.02

FY	2021
Ingresos:	$0.00
Beneficio Bruto:	$0.00 (0.00 %)
EPS:	$-2.56

FY	2020
Ingresos:	$0.00
Beneficio Bruto:	$0.00 (0.00 %)
EPS:	$-9.35

Financial Reports:

No articles found.

Oncorus, Inc.

Oncorus, Inc., a clinical-stage biopharmaceutical company, focuses on developing viral immunotherapies for cancer patients. The company's lead product candidate is ONCR-177, an intratumorally administered viral immunotherapy based on its oncolytic herpes simplex virus type 1 platform, which is in Phase I clinical trials for treating various cancers. It is also developing ONCR-GBM, a preclinical stage oHSV program for treating brain cancer through intratumoral injection; and synthetic viral immunotherapies based on Coxsackievirus A21 and Seneca Valley Virus. The company has a clinical trial collaboration and supply agreement with MSD International GmbH to evaluate the safety and tolerability of ONCR-177 combined with Merck's cancer immunotherapy KEYTRUDA in its Phase 1 clinical trial in patients with solid tumors. Oncorus, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.